Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2018-09-14 Capital/Financing Update
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
6-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. It reports the entry into an Underwriting Agreement related to a U.S. public offering of American Depositary Shares. The document includes details about the offering, underwriting agreement, and references to exhibits such as the underwriting agreement and legal opinion. The content focuses on financing activity, specifically a public offering and related underwriting agreement. The document length is 4230 characters, which is relatively short but contains substantive information about a capital raising event. This fits the definition of a Capital/Financing Update (CAP) rather than a simple announcement or regulatory filing. It is not an annual or interim report, nor a proxy or voting result. Therefore, the appropriate classification is CAP with high confidence.
2018-09-14 English
424B5 Filing
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying prospectus related to an offering of American Depositary Shares (ADSs) by Galapagos NV. It includes detailed information about the securities being registered, offering price, underwriting discounts, risk factors, use of proceeds, and other related information typical of a securities offering document. The presence of registration fee calculation, underwriting details, and offering price indicates this is a capital raising document. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an annual or interim report, earnings release, or any other type of report but specifically a prospectus supplement for a securities offering.
2018-09-14 English
MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner
M&A Activity Classification · 99% confidence The document is a press release, dated September 12, 2018, announcing the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) related to a licensing agreement between MorphoSys and Galapagos with Novartis. This type of announcement, detailing a significant corporate event (antitrust clearance for a deal) and providing context about the underlying transaction and companies, is characteristic of a general corporate announcement or regulatory filing update. Since it is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a specific management discussion (MDA), and it is a formal announcement of a regulatory milestone being cleared, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for significant, non-standard corporate disclosures. It is too detailed to be a simple Report Publication Announcement (RPA).
2018-09-13 English
MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner
Regulatory Filings Classification · 95% confidence The document is a press release dated September 12, 2018, announcing the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) related to a license agreement between MorphoSys and Galapagos with Novartis for MOR106. This announcement concerns a significant corporate transaction (licensing agreement) and regulatory clearance related to that transaction. It is not a full annual report (10-K), an interim report (IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Since it details a major corporate development involving licensing and regulatory milestones, it most closely aligns with a general corporate announcement or a filing related to corporate structure/financing, but given the context of a press release announcing a major business event, it fits best under the general 'Regulatory Filings' (RNS) category as a significant, non-standard announcement, or potentially 'Capital/Financing Update' (CAP) due to the associated upfront payment. However, RNS is the best fit for general, material, non-periodic corporate news releases that don't fit the other specific categories. The document length is substantial (7954 chars), so it is the report itself, not just an announcement of a report (RPA). Given the focus on regulatory clearance for a major agreement, RNS is the most appropriate general classification.
2018-09-13 English
Galapagos announces launch of proposed public offering
Capital/Financing Update Classification · 100% confidence The document is a press release announcing a proposed public offering of $300 million in American Depositary Shares (ADS). It details the intent to raise capital, the involvement of underwriters (Morgan Stanley and Citigroup), and references the filing of a registration statement with the SEC. This falls under the category of capital raising and financing activities.
2018-09-13 English
Galapagos announces launch of proposed public offering
Capital/Financing Update Classification · 100% confidence The document is a press release announcing a proposed public offering of American Depositary Shares (ADSs) by Galapagos NV to raise $300 million. It details the intent to sell shares, the involvement of underwriters (Morgan Stanley and Citigroup), and mentions the filing of a registration statement with the SEC. This falls under the category of capital raising and financing activities.
2018-09-13 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.